BACKGROUND: Phase I trials of the microtubule stabilising agent patupilone showed encouraging tumour control and response rates in patients with metastatic colorectal cancer. METHODS: Patients with metastatic or locally recurrent colorectal cancer who had progressed following treatment with oxaliplatin, irinotecan and fluoropyrimidines were treated with patupilone (8 mg/m(2) IV every 3 weeks) in combination with dexamethasone or prednisolone. RESULTS: The trial was closed early after 29 patients had been enrolled due to concerns about toxicity. 20 patients (71.4 %) experienced at least one grade 3-5 toxicity, most commonly diarrhoea (14 patients), dehydration (7 patients) and lethargy (6 patients). The 12 week progression-free survival rate was 16.7 % (95 % CI 6.1 %-36.5 %) in the 24 patients with a 12 week scan available or who had died prior to the 12 week scan. No complete or partial responses were seen by 12 weeks. The median progression-free survival was 2.6 months (95 % CI 2.3-2.9) and median overall survival was 6.1 months (95 % CI 3.7-8.4). CONCLUSION: Patupilone given at a dose of 8 mg/m(2) IV over 20 min every 3 weeks was associated with high levels of toxicity and no significant evidence of efficacy in patients with pre-treated colorectal cancer.
BACKGROUND: Phase I trials of the microtubule stabilising agent patupilone showed encouraging tumour control and response rates in patients with metastatic colorectal cancer. METHODS: Patients with metastatic or locally recurrent colorectal cancer who had progressed following treatment with oxaliplatin, irinotecan and fluoropyrimidines were treated with patupilone (8 mg/m(2) IV every 3 weeks) in combination with dexamethasone or prednisolone. RESULTS: The trial was closed early after 29 patients had been enrolled due to concerns about toxicity. 20 patients (71.4 %) experienced at least one grade 3-5 toxicity, most commonly diarrhoea (14 patients), dehydration (7 patients) and lethargy (6 patients). The 12 week progression-free survival rate was 16.7 % (95 % CI 6.1 %-36.5 %) in the 24 patients with a 12 week scan available or who had died prior to the 12 week scan. No complete or partial responses were seen by 12 weeks. The median progression-free survival was 2.6 months (95 % CI 2.3-2.9) and median overall survival was 6.1 months (95 % CI 3.7-8.4). CONCLUSION: Patupilone given at a dose of 8 mg/m(2) IV over 20 min every 3 weeks was associated with high levels of toxicity and no significant evidence of efficacy in patients with pre-treated colorectal cancer.
Authors: K N Chi; E Beardsley; B J Eigl; P Venner; S J Hotte; E Winquist; Y-J Ko; S S Sridhar; D Weber; F Saad Journal: Ann Oncol Date: 2011-07-16 Impact factor: 32.976
Authors: Christoph Oehler; Karl Frei; Elisabeth J Rushing; Paul M J McSheehy; Dirk Weber; Peter R Allegrini; Dorothea Weniger; Urs M Lütolf; Alexander Knuth; Yasuhiro Yonekawa; Krisztina Barath; Angela Broggini-Tenzer; Martin Pruschy; Silvia Hofer Journal: Oncology Date: 2012-06-08 Impact factor: 2.935
Authors: S Wadler; A B Benson; C Engelking; R Catalano; M Field; S M Kornblau; E Mitchell; J Rubin; P Trotta; E Vokes Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: Axel Walther; Elaine Johnstone; Charles Swanton; Rachel Midgley; Ian Tomlinson; David Kerr Journal: Nat Rev Cancer Date: 2009-06-18 Impact factor: 60.716
Authors: B Melichar; E Casado; J Bridgewater; J Bennouna; M Campone; P Vitek; J-P Delord; J Cerman; R Salazar; J Dvorak; C Sguotti; P Urban; K Viraswami-Appanna; E Tan; J Tabernero Journal: Br J Cancer Date: 2011-10-25 Impact factor: 7.640
Authors: M J Overman; L Adam; K Raghav; J Wang; B Kee; D Fogelman; C Eng; E Vilar; R Shroff; A Dasari; R Wolff; J Morris; E Karunasena; T R Pisanic; N Azad; S Kopetz Journal: Ann Oncol Date: 2018-01-01 Impact factor: 32.976